Skye Bioscience Inc [SKYE] stock is trading at $0.86, down -2.31%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SKYE shares have gain 7.24% over the last week, with a monthly amount drifted -29.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Skye Bioscience Inc [NASDAQ: SKYE] stock has seen the most recent analyst activity on October 06, 2025, when Craig Hallum downgraded its rating to a Hold but kept the price target unchanged to $2 for it. Previously, Cantor Fitzgerald downgraded its rating to Neutral on October 06, 2025, and kept the price target unchanged to $2. On August 15, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $10 on the stock. William Blair started tracking the stock assigning a Outperform rating. Scotiabank initiated its recommendation with a Sector Outperform and recommended $20 as its price target on September 30, 2024. JMP Securities started tracking with a Mkt Outperform rating for this stock on September 10, 2024, and assigned it a price target of $15. In a note dated July 09, 2024, Craig Hallum initiated an Buy rating and provided a target price of $18 on this stock.
Skye Bioscience Inc [SKYE] stock has fluctuated between $0.68 and $5.75 over the past year. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Skye Bioscience Inc [NASDAQ: SKYE] shares were valued at $0.86 at the most recent close of the market. An investor can expect a potential return of 132.56% based on the average SKYE price forecast.
Analyzing the SKYE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.81, Equity is -0.69 and Total Capital is -1.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8087 points at the first support level, and at 0.7594 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9286, and for the 2nd resistance point, it is at 0.9992.
Ratios To Look Out For
For context, Skye Bioscience Inc’s Current Ratio is 4.77. Also, the Quick Ratio is 4.77, while the Cash Ratio stands at 2.87.
Transactions by insiders
Recent insider trading involved Schwab Andrew J., Director, that happened on Aug 22 ’25 when 0.17 million shares were sold. Director, Schwab Andrew J. completed a deal on Aug 21 ’25 to sell 60956.0 shares. Meanwhile, 10% Owner 5AM Partners VII, LLC sold 0.17 million shares on Aug 22 ’25.
